Rapid oral hepatitis C test agreement
This article was originally published in The Gray Sheet
Executive Summary
OraSure Technologies and Schering-Plough will collaborate on the development and worldwide promotion of a rapid oral hepatitis C virus test using OraSure's OraQuick technology platform, the companies announced Feb. 11. The agreement expands a collaboration forged in 2007 when the parties agreed to develop a rapid HCV test for use in U.S. physicians' offices ("1The Gray Sheet" Jan. 8, 2007, In Brief). Under the terms of the agreement, Schering-Plough, which is developing hepatitis drugs, will reimburse OraSure for certain development costs and provide OraSure payments for meeting international regulatory and commercial milestones. OraSure will retain the rights to market and sell the test in all world markets, and Schering-Plough will provide promotional support